M&A Deal Summary

Glenwood Private Equity Acquires Invitros

On May 3, 2023, private equity firm Glenwood Private Equity acquired medical products company Invitros from LG Chem

Acquisition Highlights
  • This is Glenwood Private Equity’s 1st transaction in the Medical Products sector.
  • This is Glenwood Private Equity’s 3rd transaction in South Korea.

M&A Deal Summary

Date 2023-05-03
Target Invitros
Sector Medical Products
Buyer(s) Glenwood Private Equity
Sellers(s) LG Chem
Deal Type Divestiture

Target

Invitros

Seoul, South Korea
Invitros is a healthcare company specializing in in-vitro diagnostics, particularly for allergy, tuberculosis and respiratory virus infection tests.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

DESCRIPTION


DEAL STATS #
Overall 3 of 3
Sector (Medical Products) 1 of 1
Type (Divestiture) 2 of 2
Country (South Korea) 3 of 3
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-23 Olive Young

Seoul, South Korea

Olive Young is the first Korean health and beauty retailer with 1,200+ offline stores as well as a fast-growing online platform serving both domestic and global markets. Olive Young was founded in 1999 and is based in Seoul, South Korea.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-01 PI Advanced Materials

Seoul, South Korea

PI Advanced Materials (PIAM) is a producer of polyimide film for advanced industries such as display, semiconductors, and electric vehicles. PI Advanced Materials is based in Seoul, South Korea.

Sell -

Seller(S) 1

SELLER

LG Chem

Seoul, South Korea

Category Company
Founded 1947
Sector Chemicals
Employees14,011
Revenue 19.95T KRW (2023)
DESCRIPTION

LG Chem engaged in manufacture of petrochemicals like polyvinyl chloride (PVC) resins, low-density polyethylene (LDPE), poly styrene (PS), acrylonitrile butadiene styrene (ABS), bisphenol. LG Chem was founded in 1947 and is based in Seoul, South Korea.


DEAL STATS #
Overall 3 of 3
Sector (Medical Products) 1 of 1
Type (Divestiture) 3 of 3
Country (South Korea) 2 of 2
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-19 Aveo Oncology

Boston, Massachusetts, United States

Aveo Oncology is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. Aveo Oncology's product candidates are targeted against important mechanisms known or believed to be involved in cancer. Aveo Oncology was founded in 2001 and is based in Boston, Massachusetts.

Buy $571M